Immetas Therapeutics is a biotechnology company based in East Hanover, N.J., that discovers and develops novel therapeutics that modulate the innate immune system to treat age‑related cancers and inflammatory diseases. The company is building a pipeline of biologic and small‑molecule drugs internally and through collaborations, with a lead program focused on engineering bispecific antibodies to regulate inflammation in the tumor microenvironment and overcome resistance to conventional immune checkpoint therapies. Immetas emphasizes clinical evidence‑based discovery and a deep interrogation of disease mechanisms to reduce translational risk. Its scientific approach centers on targeting chronic, low‑grade inflammation as a convergent driver of aging and age‑related diseases. The company was co‑founded by J. Gene Wang, MD, PhD, and David Sinclair, PhD, who serves as a science advisor. Immetas recently closed a Series A to advance its research and pipeline.

Total raised

$11M

Funding rounds

1

Latest round

Series A

Latest activity

Sep 2020